cardiogenic shock
Cardiac failure → sustained tissue hypoperfusion (clinical + biochemical), with or without hypotension. Stage by SCAI (A–E), phenotype by ventricle (LV / RV / biventricular). ECG + echo in every patient: ischaemia → cath lab for culprit-only revascularisation; mechanical cause → fix it. Norepinephrine first if hypotensive; inotrope for low output; decongest. Call the shock centre early. No routine IABP or ECMO; microaxial pump only in selected STEMI shock. Short-term mortality 30–40%.
cardiogenic shock — first-hour bundle
- 12-lead ECG now; ST elevation or ongoing ischaemia → emergency angiography, culprit-only PCI
- TTE or POCUS: LV/RV function, regional wall motion, tamponade, acute MR, VSR, severe AS
- arterial line; central line for CVP and ScvO₂
- labs: lactate, VBG/ABG, CBC, Cr, LFTs, hs-troponin, NT-proBNP, Na⁺, K⁺, Mg²⁺, INR
- hypotensive: norepinephrine first; MAP target 60–65 mmHg
- low output with adequate MAP: dobutamine or milrinone (milrinone accumulates in renal failure)
- avoid dopamine and phenylephrine alone
- congested: IV loop diuretic ± thiazide → ultrafiltration if refractory
- stop beta-blocker, ACEi/ARNI, MRA and SGLT2i while in shock
- stage severity (SCAI B–E) and phenotype (LV, RV or biventricular) and reassess lactate and organs every 2–4 h
- inferior STEMI with clear lungs and hypotension: RV infarct — no nitrates; small fluid bolus only if RAP is low
- call the regional shock centre early: refractory shock, ≥1 vasoactive, tMCS being considered, or uncertain neurology after arrest
- no routine IABP or VA-ECMO; microaxial pump only for selected LV-dominant STEMI shock at an experienced centre
- early goals-of-care discussion; palliative care if no exit strategy
physiology
- downward spiral: ↓ cardiac output → ↓ BP → ↓ coronary perfusion → more ischaemia → ↓ output; compensatory vasoconstriction ↑ afterload → further ↓ output
- congestion injures organs too: high CVP ↓ renal perfusion pressure (MAP − CVP) and congests liver and gut → decongestion is part of resuscitation, not an afterthought
- late SIRS-like vasodilation → mixed cardiogenic + distributive shock
- normotensive shock (hypoperfusion with preserved BP from vasoconstriction) has high mortality — BP alone misses it
- every vasoactive drug raises myocardial O₂ demand and arrhythmia risk → lowest dose, shortest time
recognise
Suspect with any of: SBP <90 or MAP <60–65 for >30 min (or >30 mmHg drop, or needing drugs/devices to hold SBP ≥90), HR >100, narrow pulse pressure (<25% of SBP).
| domain | findings |
|---|---|
| perfusion — clinical | confusion, cold clammy extremities, capillary refill >2 s, urine <30 mL/h (<0.5 mL/kg/h); nausea, abdominal pain (gut ischaemia) |
| perfusion — labs | lactate >2 mmol/L, ALT >200 U/L, creatinine ≥2× ULN, pH <7.2, metabolic acidosis |
| congestion | ↑ JVP, crackles, orthopnoea, oedema — clarify LV vs RV vs both |
| ECG | ischaemia/STEMI → cath lab |
| echo / POCUS | LV or RV dilation and dysfunction, regional WMA, tamponade, acute MR, VSR, severe AS |
Also: hs-troponin, NT-proBNP, Na⁺, VBG/ABG, CBC; arterial line; central line (CVP, ScvO₂).
Causes: AMI (STEMI or NSTEMI, incl. mechanical complications) · HF-CS — acute-on-chronic cardiomyopathy or de novo (myocarditis, Takotsubo, peripartum, tachycardia-mediated) · secondary — valve lesions, tamponade, brady/tachyarrhythmia, LVOT obstruction (HCM, Takotsubo)
SCAI stages
| stage | picture | typical markers |
|---|---|---|
| A — at risk | large MI, ADHF; perfusing well | normal lactate, warm |
| B — beginning | hypotension or tachycardia without hypoperfusion | SBP <90 or HR ≥100; lactate <2 |
| C — classic | hypoperfusion needing 1 drug or device beyond fluid | lactate ≥2, creatinine ×1.5, UO <30 mL/h, cold |
| D — deteriorating | failing initial support; escalating to ≥2 drugs/device | lactate ≥4 and rising, worsening organs |
| E — extremis | circulatory collapse, CPR, ≥3 drugs/devices | lactate ≥8, pH <7.2 |
- add arrest modifier (A) if cardiac arrest
- most patients change stage within 24 h; stage B patients deteriorate most often → reassess lactate and organ function every 2–4 h early
phenotype
| LV-dominant | RV-dominant | biventricular | |
|---|---|---|---|
| haemodynamics | PCWP >15 | RAP >15 with normal PCWP; RA:PCWP >0.6; low PAPi | both ↑ |
| bedside | pulmonary oedema | ↑ JVP, clear lungs, hepatic congestion | both |
| causes | anterior MI, cardiomyopathy | inferior/RV MI, PE, pulmonary hypertension | advanced HF, large MI |
| fluid | harmful | small bolus only if RAP low; overfilling worsens LV filling (septal shift) | harmful |
- PA catheter not mandatory for diagnosis; observational data favour early complete haemodynamic profiling to guide escalation
- PEEP: ↓ LV afterload and preload → helps LV failure; ↑ PVR → harms RV failure
management
flowchart LR
A[Suspected CS<br/>hypoperfusion ± hypotension] --> B[ECG + echo/POCUS<br/>lactate, art line<br/>SCAI stage]
B --> C{Acute MI?}
C -->|yes| D[Cath lab now<br/>culprit-only PCI]
C -->|no| E{Mechanical or<br/>reversible cause?}
E -->|tamponade, acute MR/VSR,<br/>severe AS, arrhythmia| F[Drain / surgery / TAVI /<br/>cardiovert or pace]
E -->|no| G[HF-CS]
D --> H{MAP <65?}
G --> H
H -->|yes| I[Norepinephrine]
H -->|no, low output,<br/>high SVR| J[Dobutamine or milrinone]
I --> K[Add inotrope if<br/>low output persists]
J --> L[Decongest:<br/>IV loop ± thiazide → UF]
K --> L
L --> M{SCAI D/E or<br/>worsening?}
M -->|yes| N[Shock centre:<br/>tMCS by LV/RV/BiV<br/>bridge to recovery,<br/>LVAD or transplant]
M -->|no| O[Reassess q2–4 h<br/>de-escalate early]
first hour
- ECG + echo; STEMI or ongoing ischaemia → emergency angiography regardless of time from symptom onset
- shock team activation (where available); contact the regional shock centre as soon as CS is confirmed — refractory AMI-CS after local PCI, ≥1 vasoactive, tMCS being considered or uncertain neurological status after arrest → discuss transfer
- MAP target 60–65 mmHg
- early goals-of-care discussion; palliative care if no exit strategy (recovery, durable LVAD, transplant)
vasoactives
- norepinephrine first for hypotensive CS (ESC IIb; ACC consensus)
- dobutamine or milrinone for low output once MAP adequate, or in normotensive CS with high SVR; no difference in outcomes — DOREMI (2021); milrinone accumulates in renal failure and vasodilates
- avoid: dopamine (more arrhythmia; ↑ mortality in the CS subgroup of SOAP II (2010)), phenylephrine alone (↑ afterload, reflex bradycardia, ↓ output), epinephrine as first line
- inotropes not routine in hypotension without hypoperfusion (ESC III)
- dosing and receptor profiles → vasoactive drugs
temporary mechanical circulatory support (tMCS)
- no routine use — selected patients at experienced centres
- IABP: no mortality benefit in AMI-CS — IABP-SHOCK II (2012) (ESC III routine post-MI); may bridge in non-ACS CS or mechanical complications (VSR, acute MR)
- VA-ECMO: no 30-day benefit when used early in AMI-CS — ECLS-SHOCK (2023); raises LV afterload → often needs LV vent; reserved for SCAI D–E, BiV failure, fulminant myocarditis
- microaxial flow pump (Impella) in STEMI-CS: ↓ 180-day mortality (absolute 12.7%) — DanGer Shock (2024); selected LV-dominant STEMI shock — SCAI C–E, not comatose after arrest, no RV failure, vessels able to take large-bore access (ACC/AHA 2a); cost = bleeding, limb ischaemia, RRT
- RV-dominant → percutaneous RV support; BiV → VA-ECMO ± LV vent
- complications: major bleeding up to 60% in AMI-CS, limb ischaemia (×4 with tMCS) → minimise anticoagulation and access duration
- no device RCTs in HF-CS
AMI-CS specifics
- culprit-only PCI at index procedure — multivessel PCI ↑ death or RRT at 30 days in CULPRIT-SHOCK (2017); CABG if anatomy unsuitable
- new murmur + sudden shock days 1–7 → VSR or papillary muscle rupture → echo → surgery, IABP/MCS bridge
- inferior STEMI + hypotension + clear lungs → RV infarct: avoid nitrates; small fluid bolus only if RAP low
- details → STEMI management, acute coronary syndromes, post-cardiac arrest care
HF-CS specifics
- acute-on-chronic: congestion and renal failure dominate → inotrope + decongestion (IV loop ± thiazide → ultrafiltration)
- stop beta-blocker, ACEi/ARNI/MRA while shocked; SGLT2i paused; restart GDMT once off support → acute decompensated heart failure
- de novo: look for myocarditis (consider biopsy), Takotsubo with LVOTO (no inotropes or IABP — fluid if not congested, short-acting beta-blocker, Impella), peripartum
Prepared 2026-10-29. Not yet verified — check every number against the sources.